Vital Signsby BridgeheadAll voices

01  Voice · Academic · Rare diseases

Emil Kakkis, M.D., Ph.D.: no photograph is held, so the academic plate is shown instead.
Academic

Emil Kakkis, M.D., Ph.D.

CEO of Ultragenyx

Press coverage by month · bar height shows relative volume
Sept 2026Oct 2026Nov 2026to date
1

Quoted in the press, across 1 topic since 3 Sept 2026

02  Quoted on · 1 of 29 topics

Open the topic

Emil Kakkis, M.D., Ph.D.: key facts

Kind of voice
Academic
Role
CEO of Ultragenyx
Quoted on
Rare diseases
Press coverage
Quoted in the press
Most recently quoted
17 Sept 2026
First quoted
3 Sept 2026

03  Profile

04  The signal · where Emil Kakkis, M.D., Ph.D. sits on rare diseases

Quoted

Quoted in the press on rare diseases.

Placed by press coverage on this topic only, not across all topics.

  1. Giles LomaxSector leaderChief Executive Officer, Spinal Muscular Atrophy UK (SMA UK)Leading
  2. Dr Harrison CarterAcademicDirector of Screening at NHS EnglandLeading
  3. Dr Rich ScottSector leaderChief Executive Officer of Genomics EnglandLeading
  4. Laurent ServaisClinicianProfessor, University of Oxford; children's doctor and expert in rare muscle-wasting diseases
  5. David Liu portraitDavid LiuAcademicThomas Dudley Cabot Professor of the Natural Sciences at Harvard, the Broad Institute, and the Howard Hughes Medical Institute
  6. Emil Kakkis, M.D., Ph.D.AcademicCEO of Ultragenyx
  7. Jim Flett WilsonAcademicProfessor of human genetics, University of Edinburgh Usher Institute
  8. Iain HorrocksClinicianConsultant Paediatric Neurologist at NHS Greater Glasgow and Clyde

Showing the leading voices and those placed around Emil Kakkis, M.D., Ph.D. · See every voice on the topic →

05  On the record · press

What Emil Kakkis, M.D., Ph.D. has said

By outlet · bar length shows relative volume
  • blockonomi.com
  • fiercepharma.com

Where Emil Kakkis, M.D., Ph.D. has been quoted

  1. FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorderfiercepharma.com · 17 Sept 2026
  2. Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failureblockonomi.com · 3 Sept 2026

How we found the articles that name Emil Kakkis, M.D., Ph.D.: we searched news for these terms.

  • rare disease
  • rare conditions
  • orphan drugs
  • genetic disorder
  • cystic fibrosis
  • motor neurone disease
  • muscular dystrophy
  • Huntington

Also searched with “rare disease” in each of 8 national papers. Every term for Rare diseases

Verbatim

“We recognize the profound urgency of making this therapy available to families, and our focus now is on supporting timely access in the U.S. as we work closely with treatment centers and payers to support families on the gene therapy treatment journey.”
CEO of Ultragenyx · Rare diseases · fiercepharma.com · 17 Sept 2026 · Read the article
“We are disappointed for the global patient community who has invested so much in early-stage research.”
Chief Executive Officer, Ultragenyx · Rare diseases · blockonomi.com · 3 Sept 2026 · Read the article

Related media coverage

Recent UK press coverage of their topics, not necessarily citing them directly.

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.